bevantolol has been researched along with Angor Pectoris in 10 studies
bevantolol: structure given in first source
bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effects of bevantolol on stable angina pectoris of effort and its impact on metabolic risk factors, a comparison study of this beta 1-blocking agent and atenolol was undertaken in 40 subjects (mean age 51 years)." | 9.06 | Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris. ( Rauramaa, R; Salonen, JT; Salonen, R; Seppänen, K; Taskinen, E; Venäläinen, J, 1986) |
| "Bevantolol is a new beta-adrenoceptor antagonist which possesses a relatively high degree of selectivity for beta 1-adrenoceptors." | 6.37 | Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ( Benfield, P; Frishman, WH; Goldberg, RJ, 1988) |
| "The antianginal efficacy and safety of bevantolol was compared with placebo in 107 patients with angina pectoris of effort." | 5.06 | Effectiveness of bevantolol in the treatment of angina--a placebo-controlled study. ( Farnham, DJ, 1986) |
| "To assess the effects of bevantolol on stable angina pectoris of effort and its impact on metabolic risk factors, a comparison study of this beta 1-blocking agent and atenolol was undertaken in 40 subjects (mean age 51 years)." | 5.06 | Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris. ( Rauramaa, R; Salonen, JT; Salonen, R; Seppänen, K; Taskinen, E; Venäläinen, J, 1986) |
| "The efficacy and safety of bevantolol (new cardioselective beta-blocking agent without intrinsic sympathetic activity) were evaluated in chronic stable angina pectoris." | 5.06 | Acute, short- and long-term efficacy of oral bevantolol in patients with coronary artery disease: a placebo-controlled, randomized, double-blind study. ( Algarra, FJ; Bordes, P; Estruch, G; Ferrer, J; Gimeno, JV; Mainer, V; Olague, J; Serra, J, 1986) |
| "In a placebo controlled double-blind cross-over study following a dose titration phase, we compared the efficacy of benantolol, a new beta 1 adrenoceptor antagonist with alpha-adrenoceptor partial antagonist activity at 12 and 24 hours after dosing in patients with angina of effort." | 2.66 | Comparison of once and twice daily oral dosing schedules of bevantolol, a new beta-adrenoceptor antagonist with alpha-adrenoceptor partial antagonist activity in patients with angina of effort. ( Bray, CL; Hillier, V; Molajo, AO, 1989) |
| " The drug was associated with a low incidence of adverse experiences similar to that observed with placebo." | 2.66 | Safety profile of bevantolol. ( Bray, JS, 1986) |
| "Bevantolol is a new beta-adrenoceptor antagonist which possesses a relatively high degree of selectivity for beta 1-adrenoceptors." | 2.37 | Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ( Benfield, P; Frishman, WH; Goldberg, RJ, 1988) |
| "Bevantolol is a cardioselective, beta-adrenoreceptor antagonist, devoid of intrinsic beta sympathomimetic activity and with weak membrane-stabilizing and local anesthetic properties." | 1.27 | Pharmacology of bevantolol hydrochloride. ( Kaplan, HR, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Molajo, AO | 1 |
| Bray, CL | 1 |
| Hillier, V | 1 |
| Farnham, DJ | 1 |
| Bray, JS | 1 |
| Bowles, MJ | 1 |
| Khurmi, NS | 1 |
| O'Hara, MJ | 1 |
| Raftery, EB | 2 |
| Kaplan, HR | 1 |
| Salonen, JT | 1 |
| Taskinen, E | 1 |
| Salonen, R | 1 |
| Seppänen, K | 1 |
| Venäläinen, J | 1 |
| Rauramaa, R | 1 |
| Frishman, WH | 1 |
| Goldberg, RJ | 1 |
| Benfield, P | 1 |
| Rodrigues, EA | 1 |
| Lawrence, JD | 1 |
| Dasgupta, P | 1 |
| Hains, AD | 1 |
| Lahiri, A | 1 |
| Wilkinson, PR | 1 |
| Gimeno, JV | 1 |
| Ferrer, J | 1 |
| Olague, J | 1 |
| Bordes, P | 1 |
| Serra, J | 1 |
| Estruch, G | 1 |
| Mainer, V | 1 |
| Algarra, FJ | 1 |
1 review available for bevantolol and Angor Pectoris
| Article | Year |
|---|---|
Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Humans; Hypertension; Propanolamines | 1988 |
8 trials available for bevantolol and Angor Pectoris
| Article | Year |
|---|---|
Comparison of once and twice daily oral dosing schedules of bevantolol, a new beta-adrenoceptor antagonist with alpha-adrenoceptor partial antagonist activity in patients with angina of effort.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angina | 1989 |
The use of beta-adrenergic blockers in the treatment of angina and hypertension. A clinical symposium. 31st annual meeting, American College of Angiology and 21st annual meeting, International College of Angiology. San Antonio, Texas, November 6, 1984.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Clinical Trials as Topic; Humans; Hypertensio | 1986 |
Effectiveness of bevantolol in the treatment of angina--a placebo-controlled study.
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Clinical Tria | 1986 |
Safety profile of bevantolol.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Clinical Trials as Topic; Double | 1986 |
Usefulness of bevantolol for chronic, stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Chronic Disease; Double-Blind Method; Dru | 1986 |
Effects of bevantolol and atenolol on symptoms, exercise tolerance and metabolic risk factors in angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Atenolol; Blood Pressure; Double-Blind Method; | 1986 |
Comparison of bevantolol and atenolol in chronic stable angina.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Atenolol; Chronic Disease; Clinical Trial | 1988 |
Acute, short- and long-term efficacy of oral bevantolol in patients with coronary artery disease: a placebo-controlled, randomized, double-blind study.
Topics: Administration, Oral; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Coronary Disease; D | 1986 |
1 other study available for bevantolol and Angor Pectoris
| Article | Year |
|---|---|
Pharmacology of bevantolol hydrochloride.
Topics: Adrenergic beta-Antagonists; Anesthetics, Local; Angina Pectoris; Animals; Anti-Arrhythmia Agents; A | 1986 |